orgTINGO Human bionic organoid technology platform
>orgTINGO human bionic organoid technology platform
orgTINGO technology platform is dedicated to the research and application of human bionic organoids. With the independently developed iPS in vitro induction differentiation technology and tissue engineering means, a variety of complex organoid systems such as human lung, liver, small intestine and large intestine have been successfully developed. Compared with the traditional cell model and tumor organoid model, biomimetic organoids are closer to the physiological appearance of real human organs in terms of lineage diversity, structural mimicry, and functional specificity, and have great advantages in disease mechanism analysis, therapeutic target discovery, drug efficacy, drug toxicity evaluation and other aspects. In addition, these organoids are completely generated from iPS derived from somatic cell reprogramming, which not only solves the problem of limited source of primary model samples, but also can reproduce patients' own pathological characteristics in vitro, so it is especially suitable for personalized precision drug screening.
